Document is current
Any future updates will be listed below
-
Authors
Novick, Andrew M. https://orcid.org/0000-0002-0995-5060
Duffy, Korrina A.
Johnson, Rachel L.
Sammel, Mary D.
Cao, Wen
Strasser, Andrew A.
Sofuoglu, Mehmet
Kuzma, Alexandra
Loughead, James
Morrow, A. Leslie
Epperson, C. Neill
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01954966 at ClinicalTrials.govDocuments that mention this clinical trial
Effect of progesterone administration in male and female smokers on nicotine withdrawal and neural response to smoking cues: role of progesterone conversion to allopregnanolone
https://doi.org/10.1186/s13293-022-00472-w
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA036289)
National Institute on Aging (U54AG062319)
Ludeman Center for Women's Health Research, University of Colorado
- License Information
-
More Information
Article History
Received: 4 September 2022
Accepted: 15 October 2022
First Online: 23 October 2022
Declarations
:
: All participants provided either verbal or written informed consent for all study procedures. The University of Pennsylvania’s institutional review board approved all research activities.
: Not applicable.
: CNE has served on advisory boards for Asarina Pharma and Sage Therapeutics and has been a consultant and received grant support from Sage Therapeutics. ALM is a consultant for Sage Therapeutics and Pure Tech health. ALM holds a provisional patent on the anti-inflammatory actions of allopregnanolone and related steroids on toll-like receptor pathways in the immune system and brain.AMN, KAD, RLJ, MDS, WC, MS, AAS, AK, and JL reported no biomedical interested or potential conflicts of interest.
